ADCT

ADC Therapeutics (ADCT)

About ADC Therapeutics (ADCT)

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Details

Daily high

$4.28

Daily low

$3.88

Price at open

$4.15

52 Week High

$4.80

52 Week Low

$1.05

Market cap

521.5M

Dividend yield

0.00%

Volume

1.9M

Avg. volume

1.8M

P/E ratio

-2.90

ADC Therapeutics News